Janus kinase inhibitors as a breakthrough treatment for refractory dissecting cellulitis of the scalp

<b>Novel therapeutic breakthrough</b> This is one of the first documented cases demonstrating successful monotherapy with tofacitinib in refractory dissecting cellulitis of the scalp (DCS), achieving rapid and sustained remission where all standard treatments had failed.<b>Translational value for internists</b> Given the overlap between DCS and other autoimmune/inflammatory disorders commonly encountered by internists (e.g., rheumatoid arthritis, ulcerative colitis), this case supports considering Janus kinase (JAK) inhibitors for complex inflammatory dermatoses beyond current indications.<b>Clinical impact in practice</b> The case highlights the practical, off-label use of JAK inhibitors in dermatology, providing internists and multidisciplinary teams with a viable option for patients suffering from severe, treatment-resistant conditions.